SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain 6.8% Passive Stake in Kymera Therapeutics Inc.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a continued 6.8% passive beneficial ownership stake in Kymera Therapeutics Inc. as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson filed an Amendment No. 1 to Schedule 13G concerning their beneficial ownership of Kymera Therapeutics Inc. common stock.
• As of March 31, 2025, FMR LLC and Abigail P. Johnson collectively beneficially own 4,409,234.44 shares of Kymera Therapeutics Inc. common stock.
• This ownership represents 6.8% of the total outstanding common stock of Kymera Therapeutics Inc.
• FMR LLC holds sole voting power over 4,407,604.00 shares and sole dispositive power over 4,409,234.44 shares.
• Abigail P. Johnson holds sole dispositive power over 4,409,234.44 shares.
• Both reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• FMR LLC is classified as a parent holding company/control person, and Abigail P. Johnson is an individual.
• Relevant subsidiaries of FMR LLC, including FIAM LLC, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, and Strategic Advisers LLC, are identified as entities beneficially owning shares, classified as Investment Advisers or a Bank.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of passive beneficial ownership by a major institutional investor, FMR LLC, and its principal, Abigail P. Johnson. It indicates continued investment in Kymera Therapeutics Inc. without any stated intent to influence control, which is generally a neutral to slightly positive signal for the market as it confirms institutional confidence.

Positives

• FMR LLC, a major investment management firm, maintains a significant passive stake of 6.8% in Kymera Therapeutics Inc., indicating continued investment interest.
• The filing confirms that the investment is passive and in the ordinary course of business, suggesting no immediate intent to disrupt company operations or governance.

Negatives

• No negative information regarding Kymera Therapeutics Inc.'s operations or financial health is disclosed in this ownership filing.

Risks

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of Kymera Therapeutics Inc., mitigating potential governance risks from this specific shareholder.

Future Outlook

NA

Industry Context

This Schedule 13G filing primarily concerns a change in beneficial ownership percentage by a major institutional investor and does not provide specific insights into broader industry trends or competitive landscape within the therapeutics sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's passive stake, potentially reinforcing market confidence.
• Management: Confirms a stable, passive institutional investor base, reducing immediate pressure from activist shareholders.

Key Dates

Keywords

Kymera Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, passive investment, institutional investor, biotech, therapeutics